| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Pseudolaric Acid C2 is a metabolite of Pseudolaric Acid B. Its primary relevance is as a major metabolite in vivo. It may retain some biological activity of the parent compound. As a diterpenoid from Pseudolarix kaempferi, it may exhibit similar pharmacological activities to other Pseudolaric acids, including antifungal, anticancer, and anti-inflammatory properties.
|
|---|---|
| ln Vitro |
In vitro activity data for Pseudolaric Acid C2 is limited in publicly available literature. As a metabolite of Pseudolaric Acid B, it may exhibit some biological activity. It is a diterpenoid compound from Pseudolarix kaempferi. Quantitative in vitro activity data is not detailed in the available sources.
|
| ln Vivo |
In vivo, Pseudolaric Acid C2 is the predominant metabolite of Pseudolaric Acid B in plasma, urine, bile, and feces after both oral and intravenous administration to rats. It is identified as the specific metabolite of Pseudolaric Acid B. Its presence in various biological fluids indicates that it is a major metabolic product.
|
| Enzyme Assay |
For in vitro cell-free assays, Pseudolaric Acid C2 can be studied as a reference standard for identifying and quantifying the metabolite in biological samples. Its chemical properties can be characterized using HPLC-UV and HPLC-ESI/MS(n).
|
| Cell Assay |
Pseudolaric Acid C2 is not typically used in cell-based pharmacological assays as a test compound. It is primarily a metabolite and reference standard.
|
| Animal Protocol |
For in vivo studies, Pseudolaric Acid C2 is identified as the predominant metabolite in plasma, urine, bile, and feces after both oral and intravenous administration of Pseudolaric Acid B to rats. HPLC-UV and HPLC-ESI/MS(n) are used to identify and quantify the metabolite.
|
| ADME/Pharmacokinetics |
Pseudolaric Acid C2 (CAS 82508-35-8) has a molecular formula of C22H26O8 and a molecular weight of 418.44 g/mol. Chemical name: (1R,7S,8S,9R)-7-(acetyloxy)-9-[(1E,3E)-4-carboxy-4-methylbuta-1,3-dien-1-yl]-9-methyl-11-oxo-10-oxatricyclo[6.3.2.0¹,⁷]tridec-3-ene-4-carboxylic acid. Solubility: very slightly soluble (0.12 g/L) at 25°C. Density: 1.35±0.1 g/cm3 at 20°C. Storage: desiccate at -20°C. Purity: ≥95%.
|
| Toxicity/Toxicokinetics |
No toxicity data is publicly available. As a metabolite, its safety profile would be similar to that of the parent compound Pseudolaric Acid B. Standard toxicological studies would be required for drug development.
|
| References | |
| Additional Infomation |
Pseudolarix amabilis and Larix kaempferi have reportedly been found to contain pseudolarix acid C2, and relevant data are available for reference.
Pseudolaric Acid C2 is a research-grade compound and is not approved for therapeutic use. It serves primarily as a reference standard and as a tool for studying the metabolism of Pseudolaric Acid B. It is the predominant metabolite in rats after administration of Pseudolaric Acid B. No clinical trials have been reported. |
| Molecular Formula |
C22H26O8
|
|---|---|
| Molecular Weight |
418.437047481537
|
| Exact Mass |
418.162
|
| CAS # |
82508-35-8
|
| PubChem CID |
6475945
|
| Appearance |
Off-white to gray solid powder
|
| LogP |
2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
897
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O([C@]12CCC(C(=O)O)=CC[C@@]31CC[C@H]2[C@@](C)(/C=C/C=C(\C)/C(=O)O)OC3=O)C(=O)C
|
| InChi Key |
ZPSQWDVEMDWXPJ-HPHAYBORSA-N
|
| InChi Code |
InChI=1S/C22H26O8/c1-13(17(24)25)5-4-9-20(3)16-8-11-21(19(28)30-20)10-6-15(18(26)27)7-12-22(16,21)29-14(2)23/h4-6,9,16H,7-8,10-12H2,1-3H3,(H,24,25)(H,26,27)/b9-4+,13-5+/t16-,20+,21+,22-/m0/s1
|
| Chemical Name |
(1R,7S,8S,9R)-7-acetyloxy-9-[(1E,3E)-4-carboxypenta-1,3-dienyl]-9-methyl-11-oxo-10-oxatricyclo[6.3.2.01,7]tridec-3-ene-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~119.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.97 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.97 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.97 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3898 mL | 11.9491 mL | 23.8983 mL | |
| 5 mM | 0.4780 mL | 2.3898 mL | 4.7797 mL | |
| 10 mM | 0.2390 mL | 1.1949 mL | 2.3898 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
